Gorgojo-Martnez JJ, Mezquita-Raya P, Carretero-Gmez J et al (2022) Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus
2014b Blakemore, W
Forscher, die mit Cagrilintide arbeiten, ziehen hufig auch GLP-1- / Inkretin-Agonisten sowie fertige Kombinationen und Rekonstitutionslsungen in Betracht
Pharmacol Res 2018;129:109.ArticlePubMed 21
The platform's materials indicate that eligible patients typically have a BMI of 27 or higher, though individual eligibility is determined by the evaluating clinician based on each patient's complete health profile not by the platform itself
While SGLT2 inhibitors do promote modest weight loss (13 kg), their effect is less pronounced than that of GLP-1RA, and they have less impact on thyroid hormone absorption [42, 43]